search
Back to results

To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer. (THYRO-RT)

Primary Purpose

Thyroid Cancer Stage IV, Radiation Toxicity

Status
Active
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Intensity Modulated Radiotherapy
Surgery alone
Sponsored by
Tata Memorial Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Thyroid Cancer Stage IV focused on measuring locally advanced thyroid cancers, IMRT, toxicity

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A) All patients of differentiated thyroid cancer (papillary/follicular/poorly differentiated/) who have undergone total/completion thyroidectomy at our institute and having at least two of the following features (listed below) intra-operatively and/or on histopathology

  1. Gross extrathyroidal spread into soft tissues of the neck, trachea, esophagus, recurrent laryngeal nerve (constituting stage T4a)
  2. R1/ shave resections (minimal residual disease)
  3. R2 resections (gross residual disease)
  4. Multiple lymph nodes positive(>2) with perinodal extension at level VI B) Normal baseline haematological and biochemical parameters.

Exclusion Criteria:

  1. Anaplastic or medullary thyroid cancer
  2. Previous history of radiation
  3. Pregnancy
  4. < 18 years Patient unwilling to participate in the study.

Sites / Locations

  • Gouri Pantvaidya

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Intensity Modulated radiotherapy

Surgery alone

Arm Description

In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days. : The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible. The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System.

In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up

Outcomes

Primary Outcome Measures

locoregional recurrence
locoregional recurrence is defined as occurrence of pathology proven recurrence in the neck

Secondary Outcome Measures

acute toxicity
Acute toxicity will be measured during and after completion of radiation (3 months).
late toxicity
Late toxicity will be measured using the LENT-SOMA scale

Full Information

First Posted
May 4, 2018
Last Updated
April 29, 2022
Sponsor
Tata Memorial Hospital
Collaborators
Department of Atomic Energy
search

1. Study Identification

Unique Protocol Identification Number
NCT03669432
Brief Title
To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.
Acronym
THYRO-RT
Official Title
Phase II Randomized Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 2013 (undefined)
Primary Completion Date
July 2026 (Anticipated)
Study Completion Date
July 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tata Memorial Hospital
Collaborators
Department of Atomic Energy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial deals with cancers of the thyroid gland which are advanced at the local site of thyroid. These cancers are treated with surgery and complete removal of the thyroid gland. But due to advanced nature, there is risk of re-occurrence. Radiotherapy can be used to prevent this re-occurrence. This study attempt to see the effect of radiotherapy in preventing re-occurrence and its side effects in advanced thyroid cancer.
Detailed Description
Surgery, when possible offers the best chance of cure for cancer of the thyroid gland. Surgery for thyroid cancer involves removal of the thyroid gland along with removal of the lymph nodes which drain the gland. After surgery most patients will receive radio-iodine treatment to diagnose and treat any spread of the cancer in the body. Most thyroid cancers will have good outcomes with the above mentioned treatment. However, in advanced thyroid cancer there is a higher chance of recurrence even with surgery and radio iodine. Surgery for recurrence of these cancers is very morbid This may entail surgeries which may also involve removing portions of the voice box and food pipe. You may therefore develop and discomfort or inability to eat or speak. Radiation therapy can be given to the neck along with radio-iodine therapy to decrease these re occurrences of the cancer. A number of studies have shown a benefit with the use of radiation therapy in advanced cases of thyroid cancer. However, the side effects of radiation, if any, have not been well documented. This study is being done to assess the impact of radiation on the outcome of cancer and the exact side effects of radiation therapy. If the side effects are not too many, then radiation therapy can be used to decrease the chances of recurrence in the neck after thyroid. In this study, patients undergoing total thyroidectomy for thyroid cancer will be assessed for high risk features on the histopathology report and the intra operative findings. Those with advanced thyroid cancer as per the eligibility criteria will be counselled and consented for the study. Those patients willing to participate in the study will be randomised to either receive only surgery and radio-iodine or surgery, radio-iodine and external beam radiation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Cancer Stage IV, Radiation Toxicity
Keywords
locally advanced thyroid cancers, IMRT, toxicity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intensity Modulated radiotherapy
Arm Type
Experimental
Arm Description
In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days. : The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible. The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System.
Arm Title
Surgery alone
Arm Type
Other
Arm Description
In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
Intervention Type
Radiation
Intervention Name(s)
Intensity Modulated Radiotherapy
Intervention Description
The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days. : The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible. The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System.
Intervention Type
Procedure
Intervention Name(s)
Surgery alone
Intervention Description
This intervention is of no interest
Primary Outcome Measure Information:
Title
locoregional recurrence
Description
locoregional recurrence is defined as occurrence of pathology proven recurrence in the neck
Time Frame
after completion of treatment- till 5 years
Secondary Outcome Measure Information:
Title
acute toxicity
Description
Acute toxicity will be measured during and after completion of radiation (3 months).
Time Frame
during treatment- till 23 months
Title
late toxicity
Description
Late toxicity will be measured using the LENT-SOMA scale
Time Frame
at 2 years after treatment completion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A) All patients of differentiated thyroid cancer (papillary/follicular/poorly differentiated/) who have undergone total/completion thyroidectomy at our institute and having at least two of the following features (listed below) intra-operatively and/or on histopathology Gross extrathyroidal spread into soft tissues of the neck, trachea, esophagus, recurrent laryngeal nerve (constituting stage T4a) R1/ shave resections (minimal residual disease) R2 resections (gross residual disease) Multiple lymph nodes positive(>2) with perinodal extension at level VI B) Normal baseline haematological and biochemical parameters. Exclusion Criteria: Anaplastic or medullary thyroid cancer Previous history of radiation Pregnancy < 18 years Patient unwilling to participate in the study.
Facility Information:
Facility Name
Gouri Pantvaidya
City
Mumbai
State/Province
Maharashtra
ZIP/Postal Code
400012
Country
India

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.

We'll reach out to this number within 24 hrs